Catalyst Pharmaceuticals Inc. (CPRX) is owned by a number of high-value investors. Its largest direct holder is Patrick J. Mcenany Chairman of the Board, Chief Executive Officer and President with 4,772,693 shares. The second-largest direct holder is Steven R. Miller Chief Operating Officer and Chief Scientific Officer, with 657,687 shares of the company’s stock. In third place with 553,376 shares of CPRX is Charles B. O’keeffe Lead Independent Director.
Now turning to institutional ownership of Catalyst Pharmaceuticals Inc. (CPRX), Consonance Capital Management LP is the top holder with 17.0 million shares. The next largest fund holder of this company’s stock is BlackRock Fund Advisors with 6.0 million shares. In the third-place spot with 5.0 million shares is Armistice Capital LLC.
This company’s stock price was $4.66 at the previous market close, with its latest volume reaching 1544898. Compare that to its average daily volume of 2.31M. Given the fact that this stock has 101.29M shares outstanding, its current market value is sitting at $472.01M. This publicly-traded stock’s 60-month Beta is 2.37. Its Price to Sales ratio is 11.29, its Price to Cash Flow ratio is 7.88, and its Price to Book ratio is 7.52.
CPRX stock has achieved a 5-day range of $4.57 to $4.99, with a total performance of -1.48% during that period. Meanwhile, in the past month of trading, this stock has traded in the range of $4.41 to $5.83, generating a -0.43% change during the period. In the past three months, this stock’s price has changed by -9.16%, trading in the range of $4.41 to $7.67.
In the past 5 days, shares of CPRX have made a new high 1 time. In the last month, it has made a new high 11 times, and in the past 3 months, it has made a new high 14 times.
Now let’s turn to this public company’s earnings. For the quarter ending 6/29/2019, the earnings per share (EPS) was reported at 0.1. This is a 0.08 difference compared to the consensus estimate of 0.02, amounting to an earnings surprise of 400.00%. In the previous quarter, which ended in 6/29/2019, the consensus estimate was -0.13, making for an earnings surprise of 92.30%. For the quarter ending 12/30/2018, EPS was reported at -0.14, generating a -27.30% earnings surprise.
The Net Income for the most recent full fiscal year, which ended in 12-2018, was $-34.0 million. This is compared to the prior year, where Net Income was $-18.0 million. Meanwhile, this company’s Operating Cash Flow was $-25.0 million for the year, compared to $-13.0 million in 2017. Capital Expenditures for the year were reportedly $92000, and Free Cash flow was $-25.0 million compared to the prior year’s $-13.0 million.
Catalyst Pharmaceuticals Inc. (CPRX) stock currently has a Financial Strength score of 7.8/10. This is due to a combination of factors, including a Cash to Debt ratio of 55.02, an Equity to Asset ratio of 0.81, a Debt to Equity ratio of 0.02 and a Debt to EBITDA of -0.08. The Piotroski F-Score is 3, its Altman Z-Score is 18.11 and its Beneish M-Score is 84.51.
This publicly-traded company’s Profitability and Growth score is 2/10, thanks to a combination of things: an Operating Margin of -31.24, a Net Margin of -28.78, a ROE of -20.01, and a ROC of -1868.2.
Shifting focus now to Valuation and Return for CPRX, this company’s Price to Tangible Book is 7.77 and its Price to Median PS Value is 0.17. Price to Peter Lynch Fair Value for CPRX is now 0.00.
Certain ratios provide helpful insights into how a stock is performing. The Quick Ratio for CPRX is sitting at 5.07, while its Current Ratio is 5.09. This stock’s PB Ratio is 7.83, its PS Ratio is 11.73, its Forward PE Ratio is 8.75,.